HLA CLASS-II GENE-FREQUENCIES IN CROHNS-DISEASE - A POPULATION-BASED ANALYSIS IN GERMANY

Citation
M. Reinshagen et al., HLA CLASS-II GENE-FREQUENCIES IN CROHNS-DISEASE - A POPULATION-BASED ANALYSIS IN GERMANY, Gut, 38(4), 1996, pp. 538-542
Citations number
24
Categorie Soggetti
Gastroenterology & Hepatology
Journal title
GutACNP
ISSN journal
00175749
Volume
38
Issue
4
Year of publication
1996
Pages
538 - 542
Database
ISI
SICI code
0017-5749(1996)38:4<538:HCGIC->2.0.ZU;2-T
Abstract
Background-Ulcerative colitis is the only known inflammatory bowel dis ease associated with particular HLA alleles. Whereas the association w ith the HLA-DRB115 allele has been described in several independent s tudies for ulcerative colitis, no contribution of HLA alleles to susce ptibility in Crohn's disease has yet been shown. Aim-This study was de signed to study the strength of association of HLA class II alleles as risk markers for Crohn's disease in a homogenous population in German y. Patients-A total of 4251 randomly selected control subjects, and 16 2 unrelated subjects with Crohn's disease were studied. Subjects were studied for their HLA-DRB1, HLA-DQA1, and HLA-DQB1 alleles. Method-HLA DNA typing was performed after locus specific amplification with the polymerase chain reaction and reverse dot blot hybridisation. Results- The HLA-DRB107 was the only HLA class Ii allele found to be significa ntly associated with Crohn's disease (relative risk (RR)=1.9, 95% CI: 1.66 to 2.14; p=0.0001). This association remained significant after c orrection for the number of DRB1 alleles compared. In patients with di sease onset before 35 years the RR for the disease in HLA-DRB107 posi tive subjects was found to be higher (RR=3.1, 95% CI: 2.44 to 3.76). T he HLA-DRB103 was significantly decreased in frequency in Crohn's dis ease (RR=0.5, 95% CI: 0.39 to 0.61; p=0.0028). Conclusion-The HLA-DRB1 07 allele provides risk for the disease especially in patients with y ounger ages of onset. These data also provide indirect evidence for an immunogenetically based heterogeneity of the disease.